Header and Body 2

Problem Addressed

Protein-based therapeutics are one of the fastest growing pharmaceutical sectors, and recombinant proteins are widely used in fields including biotechnology research, agriculture, and food production. A major challenge in manufacturing recombinant proteins is preventing formation of aggregates. Protein aggregates are non-functional and can even be toxic in vivo, therefore it is imperative that the aggregate formation is minimized and residual aggregates removed. Optimizing production and storage conditions to prevent aggregation is currently time consuming, costly, and requires trial and error testing due to the diversity of protein structures, therefore, there is a need to develop a universal anti-aggregation solution.